Biotech Daily

Wednesday July 1, 2026

Daily news on ASX-listed biotechnology companies

*** JUNE BDI-40 UP 11%, ASX200 UP 0.5%, BIG CAPS UP 16%, NBI UP 10%**

*** TODAY: ASX DOWN, BIOTECH UP: IMUGENE, PROTEOMICS UP 22%**
- 4D MEDICAL DOWN 11%

*** ECHO IQ $110m PLACEMENT**

*** INOVIQ FALLS 54% ON EXO-OC OVARIAN CANCER SAMPLES**

*** BELLASENO TREATS 11 OF 100 BREAST REGENERATION PATIENTS**

*** UNSW DEVELOPS SOFT ROBOT HEART FOR DEVICE TESTING**

*** ADALTA PAYS $1m BZDS1901 MILESTONE**

*** MEMPHASYS $430k THAI FELIX CONTRACT**

*** ENLITIC $359k LUMUS AUSTRALIA ENSIGHT DEAL**

*** SALUDA DRAWS DOWN 2nd $36m PERCEPTIVE LOAN TRANCHE**

*** ALGORAE, NSW HEALTH SUPPLY DEAL FOR UNNAMED PRODUCTS**

*** IMUGENE 2nd PHASE Ib AZER-CEL BTK INHIBITOR COMPLETE RESPONSE**

*** SYNTARA 12 OF 20 PHASE Ib SNT-9465 SCAR PATIENTS TREATING**

*** MESOBLAST FDA REXLEMESTROCEL-L CARDIAC BLA FILING NUMBER**

*** NOXOPHARM: 'MOUSE MODEL CANCER PROGRAM'**

*** ANTEOTECH COMPLETES ANTEOBIND NXT ASSAY DEVELOPMENT**

*** EPSILON REPLACES $2m M-D LOAN WITH $1.7m M-D LOAN**

*** RECCE RECEIVES $3.7m FEDERAL R&D TAX INCENTIVE**

*** ARCHER REQUESTS 'CAPITAL RAISING' TRADING HALT**

*** TRUSCREEN 22.5m DIRECTOR OPTIONS EGM**

*** ACORN INCREASES, DILUTED TO 10% OF MICRO-X**

*** PAYNE MEDIA TAKES 6% OF MEDICAL DEVELOPMENTS**

*** ASIA UNION SELLS GENETIC SIGNATURES HOLDING**

*** CHIMERIC APPOINTS HAWKESBURY FINANCIAL ADVISORS**

*** ALGORAE: GERALDINE HOLLAND, CATHERINE EARLIE CO-CO SECS**

MARKET REPORT

The Australian stock market fell 0.64 percent on Wednesday July 1, 2026, with the ASX200 down 55.8 points to 8,722.9 points. Twenty-four of the Biotech Daily Top 40 companies were up, 13 fell and three traded unchanged.

Imugene and Proteomics were equal best, both up 2.5 cents or 21.7 percent to 14 cents, with 39.1 million shares and 1.15 million shares traded, respectively.

Impedimed climbed 20 percent; Botanix was up 15.8 percent; Compumedics and Paradigm were up more than nine percent; Immutep improved 7.55 percent; Cyclopharm climbed 6.4 percent; Micro-X and Syntara were up five percent or more; Dimerix, Mesoblast, Nova Eye, Optiscan and Saluda were up more than four percent; Actinogen, Amplia, CSL and Medical Developments were up more than three percent; Resonance and Telix rose more than two percent; with Clinuvel, Polynovo, Prescient and Starpharma up by more than one percent.

4D Medical led the falls, down 49 cents or 10.8 percent to $4.04, with 9.7 million shares traded. Artrya and Curvebeam lost more than three percent; Avita, Cochlear, EBR, Imricor and Nanosonics shed more than two percent; Emvision and Resmed fell more than one percent; with Aroa, Clarity, Neuren, Orthocell, Pro Medicus and Racura down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The first month of Australian winter was interesting - to say the least. All major indices were up after months of falls. Whether this is a ‘dead cat bounce’ or a recovery is yet to be seen. We shall know at the end of the year.

But one thing is certain: despite all the doomsayers, Australian biotechnology is on-track for a record year of capital raises.

The collective market capitalization of the four Big Caps of Cochlear, CSL, Pro Medicus and Resmed, which are not included in the Biotech Daily Top 40 Index (BDI-40), climbed 16.1 percent in June to $125,873 million – still 43.55 percent below its second highest market capitalization, last year.

Pro Medicus was the best, up $7,652 million or 56.3 percent to $21,252 million – but $8,528 million below a year ago. Cochlear rose 25.0 percent to $7,963 million, CSL was up 17.6 percent to $54,950 million, with Resmed edging up $5 million to $42,709 million.

In June, the BDI-40 climbed 11.35 percent to a collective market capitalization of $19,559 million; the benchmark ASX200 was up 0.5 percent to 8,779 points; and the Nasdaq Biotechnology Index (NBI) rose 9.6 percent to 6,565 points – up 55.3 percent for the year.

For the year to June 30, the ASX200 was up 2.8 percent, while the BDI-40 fell 3.3 percent.

But over the 20 years since Biotech Daily started the BDI-40 v ASX200 comparison, the benchmark has climbed 5,074 points or 73.0 percent, while the BDI-40 is up 448.9 percent on raw data; and 1,061.9 percent, adjusting for changes to the index (see charts below).

Again, it was a tale of two indices, with the BDI-20 up 13.7 percent in June and the Second 20 falling 3.6 percent, from much lower bases. Sixteen BDI-40 stocks rose, with eight up by more than 10 percent; while 21 fell, with 15 down by more than 10 percent.

EBR systems was June's best, up $89 million or 43.4 percent to $294 million (but 45.25 percent below its $537 market capitalization on June 30, 2025), followed by 4D Medical (36.2%), Neuren (28.9%), Telix (27.25%), Clinuvel (14.6%), Impedimed (12.5%), Dimerix (10.8%) and Paradigm (10.3%).

Cynata led the falls, following two negative trial results, down $65 million or 95.6 percent to $3 million, followed by Curvebeam (47.8%), Adheris (38.5%), Cyclopharm (34.4%), Polynovo (26.6%), Syntara (23.5%), Prescient (21.95%), Botanix (21.2%), Atomo (21.1%), Proteomics (17.4%), Actinogen (17.3%), Aroa (14.2%), Micro-X (13.3%), Clarity (11.9%) and Emvision (11.9%).

Cannabis Corner rose 22.6 percent in June to $450 million, up 89.9 percent for the year. Avecho doubled in market capitalization to $92 million on positive trial news, and was up 736.54 percent on June 30, 2025. Little Green Pharma was up 85.2 percent to $50 million on its Cannatrek takeover, followed by Bioxyne (15.4%), Cann (14.3%) and Neurotech (12.5%); while Nexalis (Inhalerx) lost 50 percent to $3 million, followed down by Vitura (26.1%) and Emyria (20%).

On the Nasdaq, Brisbane's Protagonist jumped $2,485 million or 27.9 percent to $11,397 million and up 119.0 percent on a year ago. Eyepoint (formerly Psivida) was up 9.3 percent for the month to $1,733 million and up 76.1 percent for the year to June 30, 2026.

Among the many improvements over the past 12 months, 4D Medical was the stand-out – up 2,317 percent in 12 months.

Artrya was up 1,112.2 percent in the year to June 30, 2026, Echo IQ improved 17.8 percent in June and 640.1 percent for the 12 months; Anteris climbed 505.4 percent for the year, Vitrafy was up 37.6 percent in June and 136.5 percent for the 12 months, PYC improved 24.8 percent in June and was up 119.5 percent for the year.

Although Racura (Race) fell 12.3 percent in June, it was up 113.2 percent for the year while Pacific Edge climbed 17.4 percent in June and 297.4 percent in the year to June 30, 2026. Tetratherix edged up 1.9 percent in June but was up 148.7 percent for the year.

The changes – including good and bad trial results, as well as the departure of SDI, acquired by Beijing Guoci Technology for $166.4 million - have meant major changes to the BDI-20 and Second 20.

Adheris and Cynata are demoted. Impedimed will join the Second 20, with Aroa, Dimerix and Imricor promoted to the Top 20. Artrya, Racura and Saluda will join the Second 20, with Pacific Edge, Avecho, Echo IQ, Tetratherix, Vitrafy all in contention for promotion.

BDI-40 v ASX200 Jun 30, 2006 to Jun 30, 2026- Adjusted



5-Year Big Caps $m (COH, CSL, PME, RMD) To Jun 30, 2026



BDI-40 ($m) v S&P ASX200 – Jan31, 2020 – Jun 30, 2026 (Pre-Covid to date)



ECHO IQ

Echo IQ says it has “firm commitments” to raise $110 million at $1.45 a share, an 8.8 percent discount to the last traded price.
The company said the funds would be used for US commercialization of Echosolv, product development and expanding its products to additional applications.
Echo IQ said Ord Minnett was sole lead manager to the placement and Morgans Financial was co-manager.
Echo IQ was up three cents or 1.9 percent to $1.62 with 7.9 million shares traded.

INOVIQ

Inoviq fell as much as 54.1 percent on 1,200 samples in an expanded study of its Exo-ovarian cancer (OC) test being deemed unsuitable due to significant quality variability.
Inoviq said analysis of about 1,200 samples from the case-control group of the expanded retrospective clinical study was completed but the study cohort was deemed unsuitable for performance evaluation of the Exo-OC test “due to significant variability in external sample quality across five commercial bio-repositories from multiple sites”.
The company said data analysis completed in June 2026, identified that samples from a bio-repository, which supplied 616 samples including 69 percent of the cancer cases, “exhibited reduced protein and miRNA levels consistent with sample degradation, rendering these samples unsuitable for inclusion in the study”.
Inoviq said “significant variability was identified across all bio-repositories, likely due to provider-specific pre-analytical collection and logistical factors, outside the control of the study … [but] these issues were unrelated to the performance of the Exo-Net technology or Exo-OC test”.
The company said the “study generated valuable insights into the robustness and performance of individual miRNA bio-markers under uncontrolled pre-analytical conditions, which will inform future development plans”.
Inoviq said further model tuning of Exo-OC on a previously used 500-samples showed the algorithm achieved 92.3 percent sensitivity for stage I/II ovarian cancer and 92.5 percent sensitivity at all stages, with 98 percent specificity.
Last year, the company said an independent patient validation study showed its Exo-OC blood test had “outstanding test results with accuracy of over 94 percent” in a study of more than 500 blood samples (BD: Dec 3, 2024).
Today, Inoviq said future studies would use samples collected under its standardized protocol “through a single site, nested, prospective clinical study or a real-world study conducted with a laboratory partner or [contract research organization]”.
The company said it was “committed to developing the Exo-OC test for early detection of ovarian cancer and it would “progress plans to first commercialize it as a laboratory developed test with a US laboratory partner for early detection of ovarian cancer”.
Inoviq said it had filed a provisional patent application for Exo-OC on May 29, 2026, “securing intellectual property rights covering various protein and RNA biomarker combinations and methods for the exosome ovarian cancer test”.
Inoviq chief executive officer Dr Leearne Hinch said the “exosome approach is designed to enable highly sensitive and specific detection of ovarian cancer at its earliest and most treatable stages, positioning Exo-OC as a potential screening solution”.
“We are focused on advancing development, minimizing any impact on timelines and progressing Exo-OC toward … readiness and commercialization,” Dr Hinch said.
Inoviq fell as much as 29.5 cents or 54.1 percent to 25 cents before closing down 25.5 cents or 46.8 percent at 29 cents with 6.2 million shares traded.

BELLASENO GmbH

Bellaseno says it has treated 11 of more than 100 patients in its Australian trial of 3-dimensional-printed scaffolds for restorative breast surgery, with dozens more enrolled.
The Brisbane and Leipzig, Germany-based Bellaseno said it was developing the scaffolds made from poly-capro-lactone with autologous fat grafting from the patient to restore breast volume and natural shape following the removal of implants.
A spokesperson for the company told Biotech Daily that Bellaseno's technology was based on 2011 research from the Queensland University of Technology with Munich, Germany's Technical University.
The company said that 30 Australian women had undergone restorative breast surgery using its absorbable scaffold in two trials.
Bellaseno said the scaffolds were "inserted into the breast and seeded with the patient's own fat, acting as a protective framework for tissue growth, gradually regenerating breast volume and shape over one to two years".
The company said the trial was led by surgeons and principal investigators Prof Owen Ung and Prof Anand Deva in Australia.
Bellaseno said the previous, first-in-human safety study involved 19 patients treated between 2021 and 2023 and showed no scaffold-related complications such as capsular contracture, infection, necrosis, calcification, oil cysts or scaffold removals.
The company said the study showed "patient-reported satisfaction, with 83 percent mean breast volume retention, and soft, natural-feeling tissue outcomes".
Bellaseno co-founding chief executive officer Dr Mohit Chhaya said the company's focus "had always been on building evidence through science".
Dr Chhaya said scientists, engineers, surgeons and patients believed that healthcare will increasingly involve technologies designed to unlock the body's regenerative capacity.
Bellaseno is a private company.

THE UNIVERSITY OF NEW SOUTH WALES

The University of New South Wales says it has developed a soft, robotic model of the human heart to mimic disease and provide a realistic environment for testing devices.
The University of New South Wales said the fully synthetic, soft, robotic heart reproduced "the complex movements and internal structures of the human heart, opening the door to better treatments, safer medical devices and more personalized care".
UNSW said the research introduced "a beating model of the left side of the heart that includes artificial valves, papillary muscles and chordae tendineae, structures that are critical to healthy heart function and are frequently affected by disease".
The University said the device was "able to accurately reproduce the process in a real heart where cardiac valves leak and blood flows backwards, which increases the risk of heart failure and other life-threatening complications".
UNSW said the artificial heart behaved "in ways remarkably similar to a human heart … [and] healthy valve function produced normal pressure and flow patterns, while introducing disease caused characteristic changes seen in patients".
The University said that "because the simulator offers a controllable and repeatable environment, the researchers believe it could help reduce the need for animal studies during the early stages of medical device development".
The University said the research, titled 'Compliance modulation of a soft robotic atrioventricular model of heart failure with preserved ejection fraction' was published in the journals Nature Communications and Advanced Science, with the full article available at: https://www.nature.com/articles/s41467-026-73791-w.

ADALTA

Adalta says it has paid a $US1 million milestone to Shanghai Cell Therapy Group for five additional mesothelioma patients treated with BZDS1901 cell therapy in China.
In January, Adalta said it would invest $US22million to $US31 million to develop BZDS1901 for mesothelioma outside China (BD: Jan 18, 21, 2026).
Today, the company said it had “complied with its initial financing obligations”, the payment provided access to additional data and supply of required proprietary materials.
Adalta said it expected to have a pre-investigational new drug meeting with the US Food and Drug Administration by 2027.
Adalta managing-director Dr Tim Oldham said the payment provided “access to valuable new clinical data that will support future regulatory submissions, secures the specialized materials we need to manufacture BZDS1901 in Australia, and is the final component of initial financial allocations specified in our collaboration agreement”.
Adalta was up 0.05 cents or 14.3 percent to 0.4 cents with 38.8 million shares traded.

MEMPHASYS

Memphasys says it has a three-year, minimum $430,500 distribution agreement with Bangkok’s IVF Envimed Co for its Felix sperm separation system in Thailand.
Memphasys said IVF Envimed was an in-vitro fertilization (IVF) specialist and was the exclusive distributor of IVF consumables brands including Life Global, Fertipro and Gynetic to all 110 registered IVF clinics in Thailand.
The company said the three-year contract would begin on receipt of Thai Food and Drug Administration regulatory approval, expected within about three to six months.
Memphasys said IVF Envimed was required to meet minimum purchase quantities per year, with “minimum volumes structured to increase progressively”.
The company said an initial order of 100 Felix cartridges and Felix consoles had been received “to support pre-launch marketing and clinical education activities”.
Memphasys said IVF Envimed was required to obtain Thai FDA approval “at its own cost” with Memphasys providing technical, regulatory and quality documentation.
The company said the deal brought sales for the year to June 30 to about $3.0 million.
Memphasys director Marjan Mikel said Thailand was an “important milestone”.
Memphasys was up 0.05 cents or 7.7 percent to 0.7 cents with 36.7 million shares traded.

ENLITIC

Enlitic says it has a three-year, $US248,000 ($A359,000) subscription agreement with Sydney’s Lumus Imaging for its Ensight radiology imaging system in Australia.
Enlitic said the agreement with Lumus was the first Ensight subscription in Australia “and established a deployment within a major national imaging network”.
The company said Lumus would use Ensight in three use cases including hanging protocols, which standardize how imaging studies were presented to radiologists at the point of read, de-identification, and artificial intelligence (A.I.) validation.
Enlitic said it expected to be implemented by 2027 and pricing reflected “the workflow, functionality and study-volume scope of each deployment, rather than site count alone”.
Enlitic managing-director Michael Sistenich said Lumus was “an important entry point” into Australia.
Separately, the company requested a trading halt to July 3, 2026 “pending the release of an announcement by Enlitic in relation to the outcome of a proposed capital raising”.
Enlitic last traded at 0.5 cents.

SALUDA MEDICAL

Saluda says it has dawn-down the $US25 million ($A36 million) second tranche of its $US125 million ($A181.5 million) credit facility with Perceptive Credit Holdings.
Saluda said it signed the credit agreement with Perceptive on March 14, 2025, with the first $US75 million tranche drawn-down following execution of the agreement.
The company said the third tranche of $US25 million was available through December 31, 2026, subject to certain conditions, with the proceeds from the second tranche to be used for general commercial and operating purposes.
In its initial public offer prospectus last year, Saluda said the interest rate was 7.5 percent a year, plus the greater of the one-month secured overnight financing rate and 3.5 percent, maturing on March 14, 2030.
Saluda was up two cents or 4.35 percent to 48 cents.

ALGORAE PHARMACEUTICALS (FORMERLY LIVING CELL TECHNOLOGIES)

Algorae says it has a three-year, hospital supply contract with New South Wales Health but did not disclose what products will be supplied, nor the commercial terms.
Algorae said the agreement, including scope, pricing and volumes, were confidential and that revenue would be recognized and reported in its total product revenue.
The company said it regarded the contract “as an important milestone”.
Algorae said the contract included two optional one-year extensions.
Algorae was up 0.3 cents or 30 percent to 1.3 cents with 7.8 million shares traded.

IMUGENE

Imugene says a second patient has achieved a complete response in the Bruton tyrosine kinase (BTK) inhibitor cohort of its phase Ib trial of azer-cel for blood cancers.
Last month, Imugene said it enrolled the first BTK inhibitor patient in its phase Ib basket study of its azer-cel CAR-T for various blood cancers (BD: May 28, 2026).
Yesterday, the company said one follicular lymphoma patient in the BTK inhibitor cohort of the study had achieved a complete response (BD: Jun 30, 2026).
Today, Imugene said the second patient previously received and failed BTK inhibitor therapy for mantle cell lymphoma and had a complete response at day 28 assessment.
Imugene was up 2.5 cents or 21.7 percent to 14 cents with 39.1 million shares traded.

SYNTARA (FORMERLY PHARMAXIS)

Syntara says 12 of 20 patients have begun treatment in its phase Ib study of topical pan-lysyl oxidase (pan-LOX) SNT-9465 for hypertrophic scars.
Last year, Syntara said it dosed the first volunteer in its phase Ia/b trial of SNT-9465; and later, said it began a 20-patient, phase Ib trial (BD: Jul 29, Nov 26, 2025).
Today, the company said participants were receiving blinded active treatment or placebo applied to distinct regions of the same scar, separated by buffer for the three-month treatment period, with scars evaluated using imaging and assessment tools.
Syntara said it expected top-line results in 2026 to be used for a US Food and Drug Administration investigational new drug application.
Syntara managing-director Gary Phillips said it was “encouraging to see patients coming forward for treatment and such strong engagement in the trial centres as we work towards completing recruitment [by October 2026]”.
Syntara was up 0.1 cents or five percent to 2.1 cents with 3.3 million shares traded.

MESOBLAST

Mesoblast says it has a US FDA biologics licence application file number and requests a modular review for rexlemestrocel-L in heart failure-related gastro-intestinal bleeding.
Mesoblast said the US Food and Drug Administration had provided a BLA filing number for rexlemestrocel-L in the prevention of gastro-intestinal bleeding due to right ventricular dysfunction in end-stage heart failure patients with a left ventricular assist device.
The company said rexlemestrocel-L had orphan drug designation for prevention of life-threatening major mucosal bleeding events and regenerative medicine advanced therapy status, providing eligibility for rolling and priority reviews of the BLA.
Mesoblast said “new FDA leadership this past week provided additional guidance to how it approaches regulatory flexibility for products which address orphan rare diseases with high mortality and irreversible morbidity”.
The company said the “new draft guidance to industry titled ‘Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products’ highlights FDA's flexible approach to substantial evidence of effectiveness”.
Mesoblast chief executive Prof Silviu Itescu said the company looked “forward to working closely with FDA to make rexlemestrocel-L available for the end-stage heart failure patients on mechanical devices who are at high risk of developing life-threatening gastrointestinal bleeding caused by progressive right heart failure”.
Mesoblast was up 8.5 cents or 4.35 percent to $2.04 with 4.2 million shares traded.

NOXOPHARM

Noxopharm says it has developed “a highly advanced animal model designed to accelerate its immuno-oncology program” using mice.
Noxopharm said the toll-like receptor 8 (TLR8) mouse model was developed with the Hudson Institute of Medical Research and was “believed to be the most human-relevant … model currently available anywhere in the world”.
The company said the model replicated some key features of human TLR8 biology absent in earlier models and not only incorporated the human TLR8 receptor but also reproduced where and how human TLR8 was active in the body, enabling more accurate evaluation of TLR8-targeted therapeutics.
Noxopharm fell 0.3 cents or 3.4 percent to 8.5 cents.

ANTEOTECH

Anteotech says it has completed the initial stage of immuno-assay development for its Anteobind NXT activated magnetic particles for chemiluminescent immunoassays.
Earlier this year, Anteotech said it would develop an activated particle product using Anteobind NXT for in-vitro diagnostics and immuno-assays with an unnamed “global life sciences company” (BD: Mar 3, 2026).
Today, the company said revenue from the Anteobind NXT program of $61,595 was expected to be recognized in the year to June 30, 2026, with the next stage of work agreed upon and expected to begin.
Anteotech said Anteobind NXT enhanced chemiluminescent assay sensitivity while reducing raw material consumption and lowering assay production costs by delivering uniform, oriented antibody alignment on magnetic particles.
Anteotech was up 0.4 cents or 14.3 percent to 3.2 cents with 19.45 million shares traded.

EPSILON HEALTHCARE

Epsilon says it has terminated its $2,000,000 loan from the managing-director Peter Giannopoulos-controlled Lekarna and taken a separate $1,720,000 loan from Lekarna.
Last year, Epsilon said that it had taken a $2,000,000 loan from Mr Giannopoulos at 15 percent annual interest and expiring on June 1, 2027, with directors agreeing to defer salary and fees owed to 2027 (BD: Dec 18, 2025).
Today, the company said that Lekarna had advanced $280,000 under the original note, accruing $13,940 interest at June 30, 2026, which had been converted into a separate unsecured loan.
Epsilon said the revised loan for up-to $1,720,000 at 15 percent annual interest on drawn amounts was repayable by December 31, 2027 and would be used to fund working capital, going concern support and general corporate purposes.
Epsilon was up 0.1 cents or 4.55 percent to 2.3 cents.

RECCE PHARMACEUTICALS

Recce says it has received $3,667,427 from the Australian Taxation Office under the Federal Government's Research and Development Tax Incentive program.
Recce said that the Federal Research and Development Tax Incentive related to research and development expenditure for the year to June 30, 2025, with the funds to be used for phase III clinical trial milestones.
Recce fell 2.5 cents or 6.2 percent to 38 cents with 1.1 million shares traded.

ARCHER MATERIALS

Archer has requested a trading halt "pending an announcement regarding a material capital raising".
Separately, Archer said that it had a strategic quantum compute agreement to develop quantum algorithms and applications with the College Park, Maryland-based Ionq Inc, "the world's leading quantum platform".
Trading will resume on July 3, 2026, or on an earlier announcement.
Archer last traded at 31 cents.

TRUSCREEN GROUP

Truscreen says its extraordinary general meeting will vote to issue 22,500,000 options to directors Reece O'Connell, Christine Pears, Dexter Cheung and chair Anthony Ho.
Truscreen said shareholders would vote to issue 5,000,000 options, each, to Mr O'Connell and Ms Pears and Mr Cheung, with 7,500,000 options to Mr Ho, exercisable at 1.6 cents each within 24 months from the issue date.
The company said investors would vote to ratify the prior issue of placement shares and options, broker options and shortfall shares.
The meeting will be held online on July 31, 2026 at 1pm (NZST).
Truscreen fell 0.1 cents or 7.1 percent to 1.3 cents.

MICRO-X

Acorn Capital says it has increased its substantial shareholding and been diluted in Micro-X from 71,089,457 shares (10.85%) to 72,884,701 shares (9.74%).
Melbourne's Acorn Capital said that between March 25 and 31, 2026 it sold 718,119 shares in four transactions for $41,898, or 5.8 cents a share, but did not disclose the nature of the increase in its holding.
Last year, Micro-X said it had raised $6.18 million at 8.0 cents a share in a placement, with $3.0 million from development partner Billion Prima (BD: Dec 18, 2025).
Micro-X was up 0.2 cents or 5.7 percent to 3.7 cents.

MEDICAL DEVELOPMENTS

Sydney's Payne Media says it has increased its substantial shareholding in Medical Developments from 5,933,513 shares (5.27%) to 7,100,382 shares (6.30%).
Payne Media said that it bought shares between June 4 and 30, 2026, with the single largest purchase 130,000 shares on June 30 for $52,055, or 40 cents a share.
Medical Developments was up 1.5 cents or 3.8 percent to 41 cents.

GENETIC SIGNATURES

Asia Union Investments says it has ceased its holding in Genetic Signatures following the sale of 21,312,360 shares for $1,276,632, or 6.0 cents a share.
Last month, Sydney's Asia Union said it reduced its Genetic Signatures holding from 31,312,360 shares (13.79%) to 21,312,360 shares (9.38%) (BD: Jun 16, 2026).
Genetic Signatures was up 0.1 cents or 1.5 percent to 6.8 cents.

CHIMERIC THERAPEUTICS

Chimeric says it has appointed Hawkesbury Partners as independent financial advisors "to undertake a review of strategic options available to the company".
Chimeric said it was "actively reviewing all strategic and funding options with the objective of maximizing shareholder value".
The company said it had invested more than $80 million in building its clinical programs and manufacturing, quality and regulatory infrastructure.
Chimeric said it believed "the value embedded in this portfolio is not currently reflected in the company's market capitalization".
The company said the advisors would "identify and evaluate opportunities to realize and maximize the value of Chimeric and its assets for the benefit of shareholders … [including] strategic partnerships and funding, licencing arrangements, co-development agreements, mergers, asset sale transactions and alternative capital structures".
Chimeric said there was "no certainty any transaction will result from this process and Chimeric will update the market on material developments as the arise".
Chimeric fell 0.8 cents or 12.3 percent to 5.7 cents.

ALGORAE PHARMACEUTICALS (FORMERLY LIVING CELL TECHNOLOGIES)

Algorae says it has appointed Geraldine Holland and Catherine Earlie as joint company secretaries, effective from today, replacing Jennifer Voon who will step down.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT JUN 30, 2026

Company $Am	Jun 30, 2025	May 31, 2026	Jun 30, 2026
Cochlear	19,647	6,370	7,962
CSL	115,959	46,737	54,950
Pro Medicus	29,780	13,600	21,252
Resmed	57,595	41,704	41,709
BDI-20			
4D Medical	112	1,987	2,707
Aroa	200	240	206
Avita	227	181	185
Clarity	804	906	798
Clinuvel	520	452	518
Compumedics	49	54	51
Cyclopharm	101	90	59
Dimerix	341	111	123
EBR Systems	537	205	294
Immutep	350	78	78
Imricor	487	620	652
Medical Developments	62	43	45
Mesoblast	2,115	2,628	2,531
Nanosonics	1,230	953	995
Neuren	1,750	1,745	2,250
Nova Eye	31	31	30
Orthocell	286	208	197
Polynovo	826	867	636
Syntara	86	51	39
Telix	8,263	4,422	5,627
Second 20			
Actinogen	73	139	115
Alcidion	134	144	141
Amplia	78	69	74
Artrya	82	791	994
Atomo	10	19	15
Botanix	627	66	52
Curvebeam	28	23	12
Emvision	149	160	141
Impedimed	71	16	18
Imugene	97	48	48
Lumos	20	107	99
Micro-X	33	30	26
Optiscan	92	123	125
Paradigm	119	87	96
Prescient	35	82	64
Proteomics	53	23	19
Racura Oncology	204	496	435
Resonance	18	20	21
Saluda	89	91	116
Starpharma	37	295	295

* Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Amplia, Clarity, Cochlear, EBR, Nanosonics, Neuren, Patrys, Percheron, Polynovo and Telix, as well as unlisted and non-biotech stocks.
Through Australian Ethical Superannuation he has an indirect interest in other companies:
https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/. These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 500, Flemington, Victoria, Australia, 3031
email: editor@biotechdaily.com.au; www.biotechdaily.com.au